ClinicalTrials.gg
RecruitingNCT04545762Updated Oct 26, 2026

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 1 interventional study of Fludarabine and Cyclophosphamide in Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma and Mantle Cell Lymphoma, sponsored by C. Babis Andreadis. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by C. Babis Andreadis · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.
Updated Oct 26, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States — 137 open to participants now, 253 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Planned enrollment
667th of 1,378
36 · median 35
Started
2020
with 44 others
Phase 1
529 of 1,600
48 open now
Primary completion
2026-10
later than 67 of 248 live
Registered
1,361st of 1,600
by date

Among the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 667th largest by planned enrollment of the 1,378 interventional ones that give a count, is one of 45 that started in 2020, is one of 529 in phase 1, reaches primary completion later than 67 of the 248 other live ones, and was the 1,361st registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

137 of the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

Read the detailed description

This is an open-label, pilot, phase 1 study to determine the safety profile of anti-CD19 CAR-T cell infusion in participants with R/R B-cell NHL.

PRIMARY OBJECTIVES

  1. To evaluate the safety of administering chimeric antigen receptor T cells targeting CD-19 to patients with relapsed or refractory CD19+ B-cell non-Hodgkin lymphoma (NHL).
  2. To determine the recommended phase 2 dose (RP2D) for this cellular therapy.

SECONDARY OBJECTIVES

  1. To assess the safety and toxicity of cell collection and infusion of CAR-T cells targeting CD19 in patients with relapsed or refractory CD19+ B cell NHL.
  2. To describe the efficacy of chimeric antigen receptor T cells targeting CD-19 in patients with relapsed or refractory CD19+ B cell NHL.
  3. To evaluate the feasibility of CD19 CAR T cell manufacturing for patients with relapsed or refractory CD19+ B cell NHL of local manufacturing and ability to produce adequate quantities of vector positive T-cells.

OUTLINE

Participants will be enrolled to either the dose escalation or dose expansion cohorts.

Dose Escalation: CLOSED TO ENROLLMENT

Dose Expansion: The dose expansion phase of the study will be limited to two disease-specific cohorts:

  • Cohort B: Participants with Burkitt lymphoma (B).
  • Cohort M/W: Participants with Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM).

Participants will receive an infusion of Anti-CD19 CAR-T cells during the main study and will be followed for 12 months before being transferred into long term follow-up during years 1 to 15.

03

Conditions studied

  • Refractory Non-Hodgkin Lymphoma
  • Burkitt Lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Primary Mediastinal Large B Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Small Lymphocytic Lymphoma
  • Transformed Lymphoma
  • Non-Hodgkin Lymphoma

Keywords

  • CAR-T Therapy
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

THE DOSE ESCALATION COHORT IS CLOSED TO FURTHER ENROLLMENT.

Inclusion criteria

Inclusion Criteria:

Dose expansion Cohorts:

Cohort B (Burkitt):

  1. Participants must have a diagnosis of Burkitt Lymphoma o Participants with Burkitt lymphoma must have relapsed or failed to respond to at least 1 prior line of multiagent chemoimmunotherapy with prior exposure to both an anti-CD20 antibody agent and an anthracycline.

    o No significant circulating disease, defined as an elevated total lymphocyte count above the (ULN) due to the presence of malignant cells.

  2. Participants must have as defined below:

    • Participants with Burkitt Lymphoma must have Positron Emission Tomography (PET)-positive disease according to "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"

Cohort M/W (Marginal/Waldenström):

  1. Participants must have a diagnosis of relapsed or refractory Marginal Zone Lymphoma (MZL), or Lymphoplasmacytic Lymphoma (LPL)/Waldenström Macroglobulinemia (WM):

    o Participants with indolent lymphomas (nodal or extranodal marginal zone lymphoma, and lymphoplasmacytic lymphoma) must have relapsed after or have been refractory to ≥ 2 prior lines of multi-agent chemoimmunotherapy including prior exposure to an anti-CD20 antibody and an alkylating agent.

  2. Participants must have measurable disease as defined below:

    • Participants with Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: must either have PET-positive disease according to "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" or serum monoclonal immunoglobulin M (IgM) paraprotein > 0.5 g/dL.
  3. Participants with indolent lymphoma (Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia) must have symptomatic disease or steady progression necessitating systemic treatment per investigator discretion.

In addition, all participants must meet the following criteria:

  1. CD19-positive by either immunohistochemistry or flow cytometry analysis on any . If prior anti-CD19 therapy has been administered, CD19-positivity has to be re-established on the most recent biopsy.
  2. Age ≥18 years at the time of consent.
  3. Absolute lymphocyte count > 100/UL.
  4. (ECOG) performance status \< 2.
  5. Adequate organ function, defined as:

    o (ALT)/aspartate aminotransferase (AST) \< 3 x institutional upper limit of normal (ULN) and Total \< 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome

    o Serum Creatinine \< 2 x the institutional ULN

    o Adequate cardiac function, defined as (LVEF) > 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA) within 3 months of screening. Repeat testing may occur at Investigator's discretion.

    a. Adequate bone marrow function for apheresis and lymphodepleting chemotherapy

  6. Adequate hematologic function, defined as:

    • >8 gm/dl (transfusions allowed)
    • >50,000/uL (transfusions allowed)
    • (ANC) > 500/uL

Note: These criteria must be met and documented at least once during the screening period. Participants are not required to continue to meet these laboratory thresholds through initiation of study treatment. If a laboratory value subsequently falls below the specified threshold due to a transient or reversible clinical circumstance, the Principal Investigator may determine that the participant remains eligible, based on clinical assessment of the participant's underlying hematologic function and the safety of proceeding with study treatment.

6. Adequate vascular access for leukapheresis procedure (either peripheral line or surgically placed line).

7. Women of (defined as all women physiologically capable of becoming pregnant) must have a negative serum or urine pregnancy test AND agree to use highly effective methods of for 1 year after the last dose of anti-CD19 CAR-T cells.

8. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method.

9. Ability to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  1. transplant within 6 weeks of planned CAR-T cell infusion.
  2. Recipient of prior CAR-T cell therapy targeting CD19 outside of this protocol.
  3. Active other , other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast).
  4. (HIV) seropositivity.
  5. Serologic status reflecting active or C infection. Participants that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive participants will be excluded.)
  6. Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. NOTE: Women of must have a negative serum or urine pregnancy test.
  8. Participants with history of central nervous system (CNS) pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.
  9. History of disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) with requirement of medication within 6 months.
  10. Body weight \<40 kilograms(kg).

Eligibility for Infusion of Product:

Participants will undergo an evaluation of eligibility on day 1 prior to infusion of anti-CD19 CAR-T cell product. This eligibility criterion will include the inclusion and exclusion criteria required for enrollment with the following exceptions and additions:

  1. No significant laboratory abnormalities. Laboratory result abnormalities that are considered not clinically significant by the principal investigator AND are not the result of a demonstrated active infection or an active central nervous system condition.
  2. performance status \< 2
  3. No evidence of uncontrolled intercurrent illness including, but not limited to ongoing or active infection, inflammatory response, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations.
  4. No new neurologic symptoms suggestive of an active central nervous system condition, or uncontrolled CNS involvement by lymphoma.
  5. No use within 7 days prior to infusion (with exception of agents used for prevention of emesis during lymphodepletive chemotherapy).
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    CLOSED TO ENROLLMENT: Dose escalation (CART-T Therapy)

    Participants will undergo Apheresis (1 day) to collect autologous lymphocytes/ mononuclear cells as per University of California, San Francisco (UCSF) institutional practices. CAR-T cell manufacturing (estimated \~13-14 days), during which participants will receive a lymphodepleting regimen of immunosuppressive chemotherapy (Cyclophosphamide 300 mg/m2/IV and fludarabine 30 mg/m2 /IV) followed by the infusion of CAR-T cells at an initial dose of 5 x 10\^5 cells/kg, targeting CD19 over 5-30 minutes. Participants will be followed up 30 days after infusion, for up to 12 months, if the participant in continued remission, and for survival up to 15 years.

  • Experimental
    Dose Expansion: Burkitt, Marginal Zone, or Waldenström Macroglobulinemia ONLY (CAR-T Therapy)

    Participants with Burkitt lymphoma, or Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM) will undergo Apheresis (1 day) to collect autologous lymphocytes/ mononuclear cells as per University of California, San Francisco (UCSF) institutional practices. CAR-T cell manufacturing (estimated \~13-14 days), during which participants will receive a lymphodepleting regimen of immunosuppressive chemotherapy (Cyclophosphamide 300 mg/m2/IV and fludarabine 30 mg/m2 /IV) followed by the infusion of the maximum tolerated dose of CAR-T cells established in the dose escalation phase, targeting CD19 over 5-30 minutes. Participants will be followed up 30 days after infusion, for up to 12 months, if the participant in continued remission, and for survival up to 15 years.

    Drug: Fludarabine · Drug: Cyclophosphamide · Biological: anti-CD19 CAR-T cells

Interventions

  • Given intravenously (IV)

    Also known as: Fludarabine 30mg/m2, Fludara

  • Given intravenously (IV)

    Also known as: Cyclophosphamide 300mg/m2, Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin

  • BiologicalAnti-CD19 CAR T Cells PreparationStudies of Anti-CD19 CAR T Cells PreparationAnti-CD19 CAR T Cells Preparation pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single infusion

    Also known as: CD19-directed Chimeric Antigen Receptor T-Cell (CAR T-cell) therapy, CD19-directed chimeric antigen receptor (CAR) T-cell therapy

06

What researchers measure

Primary outcomes

  1. Proportion of participants with treatment-emergent adverse events (AEs)

    Participants treated with conforming product who received the target doses of anti-CD19 CAR-T infusion will be included in the analysis. Proportion of participants with treatment-emergent adverse events of CAR-T in B-cell NHL, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0), revised Cytokine Release Syndrome (CRS) grading criteria, and American Society for Transplantation and Cellular Therapy (ASTCT) immune effector cell (IEC) -associated neurotoxicity syndrome (ICANS) Consensus Grading for Adults (for neurotoxicity grading).

    Time frame: From initiation of study treatment to 12 months following CAR-T infusion, approximately 15 months

  2. Proportion of participants who experience a dose-limiting toxicity (DLT) (Dose escalation)

    A DLT includes AEs graded according to CTCAE version 5.0, with the exceptions of CRS and neurotoxicity, which are graded using CRS and ICANS criteria. DLTs must 1) be suspected to be secondary to CAR-T cell infusion, 2) occur during the first 30 days after infusion and 3) meet the following criteria: 1. Grade 3 or 4 non-hematologic toxicities of any duration, with following exceptions: Grade 3 laboratory abnormalities without associated symptomatology or clinical consequence that resolve in \< 7 days; AEs associated with Grade \<= 2 CRS; Toxicities associated with Grade 3 CRS (except cardiac or pulmonary organ toxicity) that improves to grade \<= 2 within 3 days of intervention; isolated renal or hepatic grade 3 organ toxicity that does not resolve within 7 days; Laboratory abnormalities compatible with tumor lysis syndrome; Grade 4 hematological toxicity that persists at grade \>= 3 despite maximum supportive care for \>21 days.

    Time frame: From initiation of study treatment to 30 days following CAR-T infusion

Secondary outcomes

  1. Proportion of participants with CAR-T infusion related adverse events (Dose Escalation)

    The proportion of participants with adverse events related to the collection and infusion of CAR-T cells targeting CD19 will be reported.

    Time frame: From initiation of CD19 CAR T-cell manufacturing to end of infusion, approximately 18 days

  2. Proportion of participants with delayed infusion due to study-related adverse events

    The proportion of participants who have their infusion delayed due to and AE will be reported.

    Time frame: From T-cell collection to end of infusion, approximately 18 days

  3. Overall Response Rate (ORR)

    Overall response rates will be reported as proportions of participants by arm. The 2014 Lugano Response for Malignant Lymphoma criteria will be to determine response: Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Relapse and Progression (PD). For the Waldenstrom's Macroglobulinemia cohort, the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) response criteria will be used to determine response: CR, very good partial response (VGPR), PR, minor response (MR), SD, and PD.

    Time frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months

  4. Complete Response Rate

    Complete response rates will be reported as will be reported as proportions of participants by arm.

    Time frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months

  5. Partial Response Rate

    Partial response rates will be reported as will be reported as proportions of participants by arm.

    Time frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months

  6. Median duration of response

    For participants who have been documented to be responders under the 2014 Lugano criteria or the IWWM-11 criteria, and defined as the median time from the documented beginning of response (CR or PR) to the time of relapse.

    Time frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months

  7. Median Progression-free Survival (PFS)

    PFS is defined as the median time from entry onto study until a diagnosis of lymphoma progression or death from any cause at 12 months after receiving CAR-T infusion.

    Time frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months

  8. Median Overall Survival

    Defined as the median time from entry onto study until death from any cause

    Time frame: Up to 15 years

  9. Proportion of participants for whom CD19 CAR T-cell therapy is manufactured

    The proportion of participants for whom CD19 CAR T-cell therapy is adequately manufactured and meets pre-specified release criteria.

    Time frame: From initiation of CD19 CAR T-cell manufacturing to end of infusion, approximately 18 days

  10. Proportion of participants who complete study treatment

    Feasibility will be assessed by the proportion of participants who are able to complete the study regimen and receive infusion of CAR-T therapy.

    Time frame: From initiation of CD19 CAR T-cell manufacturing to end of infusion, approximately 18 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Oct 2026, 73 months after the start.

Of 123 non-industry phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 80. This study's planned 73 months is above that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Sep 11, 2020
StartActual
Sep 11, 2020
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
6 inclusion criteria edited, 2 added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedParticipants must have a diagnosis of relapsed or refractory Burkitt Lymphoma
  • EditedParticipants must have a diagnosis of relapsed or refractory Burkitt Lymphoma o Participants with Burkitt lymphoma must have relapsed or failed to respond to at least 1 prior line of multiagent chemoimmunotherapy with prior exposure to both an anti-CD20 antibody agent and an anthracycline.
  • Editedo No significant circulating disease, defined as an elevated total lymphocyte count above the upper limit of normal (ULN) due to the presence of malignant cells.
  • Editedo Participants with Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: must either have PET-positive disease according to "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" or serum monoclonal immunoglobulin M (IgM) paraprotein > 0.5 g/dL.
  • Editedo alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x institutional upper limit of normal (ULN) and Total bilirubin < 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome
  • Editedo Serum Creatinine < 2 x the institutional ULN
  • Editedo Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) > 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA) within 3 months of screening. Repeat testing may occur at Investigator's discretion.
  • AddedAdequate hematologic function, defined as:
  • AddedNote: These criteria must be met and documented at least once during the screening period. Participants are not required to continue to meet these laboratory thresholds through initiation of study treatment. If a laboratory value subsequently falls below the specified threshold due to a transient or reversible clinical circumstance, the Principal Investigator may determine that the participant remains eligible, based on clinical assessment of the participant's underlying hematologic function and the safety of proceeding with study treatment.
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Eligibility 6 inclusion criteria edited, 2 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedParticipants must have a diagnosis of relapsed or refractory Burkitt Lymphoma
    • EditedParticipants must have a diagnosis of relapsed or refractory Burkitt Lymphoma o Participants with Burkitt lymphoma must have relapsed or failed to respond to at least 1 prior line of multiagent chemoimmunotherapy with prior exposure to both an anti-CD20 antibody agent and an anthracycline.
    • Editedo No significant circulating disease, defined as an elevated total lymphocyte count above the upper limit of normal (ULN) due to the presence of malignant cells.
    • Editedo Participants with Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: must either have PET-positive disease according to "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" or serum monoclonal immunoglobulin M (IgM) paraprotein > 0.5 g/dL.
    • Editedo alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x institutional upper limit of normal (ULN) and Total bilirubin < 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome
    • Editedo Serum Creatinine < 2 x the institutional ULN
    • Editedo Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) > 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA) within 3 months of screening. Repeat testing may occur at Investigator's discretion.
    • AddedAdequate hematologic function, defined as:
    • AddedNote: These criteria must be met and documented at least once during the screening period. Participants are not required to continue to meet these laboratory thresholds through initiation of study treatment. If a laboratory value subsequently falls below the specified threshold due to a transient or reversible clinical circumstance, the Principal Investigator may determine that the participant remains eligible, based on clinical assessment of the participant's underlying hematologic function and the safety of proceeding with study treatment.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04545762
Lead sponsor
C. Babis Andreadis
Responsible party
C. Babis Andreadis (Professor of Clinical Medicine, University of California, San Francisco) — Sponsor-investigator
First posted
Sep 11, 2020
Start date
Sep 11, 2020
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

UCSF HDFCCC Cancer Immunotherapy Program
Contact
HDFCCC.CIP@ucsf.edu
877-827-3222
Carrie Ho, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19 CAR T Cells Preparation

Start the discussion